Gatifloxacin for injection

1Gatifloxacin belongs to the fourth generation of quinolone antibacterial drugs. 2This product is a racemic compound of 8-methoxyfluoroquinolone, which has a broad spectrum of activity against Gram-negative and Gram-positive microorganisms in vitro, and its R- and S-enantiomers have the same antibacterial activity. This product's antibacterial effect is through inhibiting bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes.

The main ingredient of this product is: Gatifloxacin.

Used to treat the following infectious diseases of moderate severity or above caused by sensitive strains: 1. Acute exacerbation of chronic bronchitis: caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis or Staphylococcus aureus. 2. Acute sinusitis: caused by Streptococcus pneumoniae and Haemophilus influenzae. 3. Community-acquired pneumonia: caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Staphylococcus aureus, Chlamydia pneumophila, Mycoplasma pneumophila or Legionella pneumophila. 4. Simple or complicated urinary tract infection (cystitis): caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, etc. 5. Pyelonephritis: caused by Escherichia coli, etc. 6. Simple urethral and cervical gonorrhea: caused by Neisseria gonorrhoeae. 7. Acute simple rectal infection in women: caused by Neisseria gonorrhoeae. Before treatment, appropriate culture and sensitivity tests should be performed to isolate and identify the pathogenic microorganisms and determine their sensitivity to gatifloxacin. However, treatment with this product can be started before the results of the bacteriological examination are obtained. After the results of the bacteriological examination are obtained, appropriate treatment can be continued.

Intravenous drip, 400 mg each time, once a day. This product is a powder injection, which can be used after being dissolved and diluted to 2 mg/ml with 5% glucose injection or 0.9% sodium chloride injection. This product is bioequivalent to oral tablets. During the course of treatment, it can be changed from intravenous administration to oral tablets according to the doctor's decision, and there is no need to adjust the dose. Gatifloxacin is mainly excreted through the kidneys. Patients with creatinine clearance < 40ml/min, including hemodialysis and long-term peritoneal dialysis patients, should adjust the dose of this product. Hemodialysis patients should take the drug after each hemodialysis. Patients with renal insufficiency use a single dose of 400 mg to treat simple urinary tract infection or gonorrhea, and 200 mg daily for 3 days to treat simple urinary tract infection, without adjusting the dose of this product.

1. If you feel unwell during the use of this product, tell your doctor or pharmacist as soon as possible. If the situation is urgent, you can stop taking the medicine first. 2. If the medicine is used properly, the medicine can bring you satisfactory therapeutic effects. It may also cause some adverse reactions, but not everyone will experience them. You may not encounter any of them, so don't be nervous. The following are possible adverse reactions of gatifloxacin: 1. Digestive system: nausea, abdominal pain, constipation, indigestion, glossitis, candidal stomatitis, stomatitis, oral ulcers, vomiting, diarrhea, pseudomembranous colitis. 2. Cardiovascular system: palpitations. 3. Metabolic and nutritional system: peripheral edema. 4. Nervous system: dreaminess, insomnia, paresthesia, tremor, vasodilation. 5. Respiratory system: dyspnea, pharyngitis. 6. Skin and skin soft tissue: rash, sweating. 7. Urogenital system: dysuria, hematuria, vaginitis. 8. Special senses: visual abnormalities, taste abnormalities, tinnitus. 9. Allergic reactions: quinolones can sometimes cause severe or even fatal allergic reactions. 10. Chills, fever, back pain and chest pain. 11. In animal tests and clinical trials, phototoxicity was not observed at the recommended dose level. However, some patients have experienced phototoxic reactions after receiving certain quinolones. Be vigilant. 12. After gatifloxacin was launched, it has been reported that a very small number of patients treated with gatifloxacin had severe blood sugar abnormalities. These abnormalities include hyperosmolar non-ketotic hyperglycemic coma, diabetic ketoacidosis, hypoglycemic coma, convulsions and changes in mental status (including loss of consciousness). Although a few have led to fatal consequences, most of these events are reversible if properly treated. 13. Quinolones can cause central nervous system abnormalities, such as tension, excitement, headache, dizziness, insomnia, anxiety, nightmares, increased intracranial pressure, etc. 14. This product increases the risk of central nervous system irritation symptoms and convulsions, and may cause dizziness and mild headaches, which may affect driving a car, working at heights, operating machinery, or engaging in other work that requires alertness or coordination of the mental and nervous system.

(1) Do not stop taking this product or reduce the dosage without consulting a physician. (2) This product is contraindicated in patients who are allergic to either this product or any quinolone drug.

1. This product can be used in combination with probenecid to slow down the renal elimination of gatifloxacin. 2. When this product is used simultaneously with digoxin, no significant changes in the pharmacokinetics of gatifloxacin are observed, but increased digoxin blood concentrations are found in some subjects. Therefore, patients taking digoxin should be monitored for symptoms and signs of digoxin toxicity. For patients who show symptoms and signs of toxicity, the blood concentration of digoxin should be measured and the digoxin dose should be adjusted appropriately. However, it is not recommended to adjust the doses of the two drugs in advance. 3. The simultaneous use of gatifloxacin and drugs that affect glucose metabolism can increase the risk of abnormal blood glucose metabolism in patients (see Contraindications and Warnings: Abnormal Blood Glucose). Antidiabetic drugs: Pharmacodynamic changes that affect glucose metabolism have been observed after the combined use of glibenclamide and other hypoglycemic drugs. No significant pharmacokinetic interactions were observed when glibenclamide was used in combination with gatifloxacin.

Keep away from light, tightly closed, in a cool and dry place.

0.2g

Nanjing Sanhome Pharmaceutical Co., Ltd.

• Founded in:

  1996-09-19

• Address:

  No. 9 Huizhong Road, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192608959455D

• Registered Funds:

  430 million yuan

• Website:

  Log in to view

• Email:

  Log in to view